Annual report pursuant to Section 13 and 15(d)

INVENTORIES

v3.24.0.1
INVENTORIES
12 Months Ended
Dec. 31, 2023
INVENTORIES  
INVENTORIES

6. INVENTORIES

The following table summarizes inventories, net (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

As of December 31,

​

​

2023

    

2022

Raw materials

​

$

4,609

​

$

4,555

Work in process

​

​

1,876

​

​

2,659

Finished goods

​

​

1,508

​

​

1,904

Total

​

$

7,993

​

$

9,118

Reported as:

​

​

​

​

​

​

Inventories

​

$

5,522

​

$

9,118

Other assets

​

​

2,471

​

​

—

Total

​

$

7,993

​

$

9,118

​

Inventories as of December 31, 2023 and 2022 include inventories acquired from Forma pursuant to the license and transition agreement. As of December 31, 2023 and 2022, zero and $0.8 million, respectively, of advance payments to the manufacturer of our raw materials were included within prepaid and other current assets in the balance sheet.

Non-current inventories consist of active pharmaceutical ingredient classified as raw materials which have multi-year shelf life, as well as certain work in process and finished goods inventories that are not expected to be consumed beyond our normal operating cycle.